US EditionKCK pharmaceutical company completes reverse stock split
Summary by The Business Journals
1 Articles
1 Articles
All
Left
Center
1
Right
KCK pharmaceutical company completes reverse stock split
“(Cingulate) collectively decided that we wanted to put the minimum bid compliance issue with Nasdaq behind us and focus on some of the exciting catalysts ahead in the first quarter of next year,” said Thomas Dalton, the company's vice president of investor and public relations.
·United States
Read Full ArticleCoverage Details
Total News Sources1
Leaning Left0Leaning Right0Center1Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
